secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001193125-24-240585
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham
--------------------------------------------------------------------------------

- ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).
- In overall Phase 2 ARCHER, ANX007 monthly reduced 15+ letter loss to 6% (5/89) vs 21% (19/89) sham (p=0.0021).
- ANX007 showed 61% decrease in EZ loss in patients with <80% EZ intact at baseline (p=0.0575).
- Pivotal Phase 3 ARCHER II data expected in second half 2026.
- ANX007 is a first-in-kind Fab targeting C1q intravitreally; data presented at AAO 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524240585/0001193125-24-240585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524240585/d849436d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-240585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer